MiStent® coronary drug-eluting stent system, as an important overseas transformation project of Kossel Medtech (Suzhou) Co., Ltd., has officially landed in the Chinese market with two advantages of “fast healing and long efficacy”, providing a new clinical choice for PCI surgery.
Fast healing: Thin-wall stent + degradable coating, rapid endothelialization, reduce chronic inflammation and stent thrombosis;
Long efficacy: Sirolimus drug crystal, controlled, slow release up to 9 months, reduces late stent lumen loss.

The reason why MiStent® coronary drug-eluting stent system can have the above two characteristics at the same time is the unique coating process – supercritical fluid coating technology.
With the addition of this coating process, Sirolimus can be uniformly distributed in the absorbable PLGA polymer in a “crystal” form. In the early stage of stent implantation, drug release is low and rapid endothelialization is achieved. In the later stage, with the degradation of the polymer, the drug crystals dissolve slowly, inhibit the proliferation of smooth muscle, and maintain the long-term patency of the lumen.

MiStent® bracket “3+2” biscuit coating structure